product name Fluocinonide
Description: Fluocinonide is a potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin disorders such as eczema. Fluocinonide cream has a lower potential to produce atrophic changes of the skin than either clobetasol cream or clobetasol propionate foam. It relieves itching, redness, dryness, crusting, scaling, inflammation, and discomfort.
References: J Drugs Dermatol. 2008 Jan;7(1):28-32; J Drugs Dermatol. 2008 Jan;7(1):28-32.
494.52
Formula
C26H32F2O7
CAS No.
356-12-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 99 mg/mL (200.2 mM)
Water: <1 mg/mL
Ethanol:
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19422767
| In Vitro |
In vitro activity: Fluocinonide cream has a lower potential to produce atrophic changes of the skin than either clobetasol cream or clobetasol propionate foam. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Fluocinonide causes prompt and sustains pituitary-adrenocortical suppression in healthy dogs. Fluocinonide results in significant reduction of plasma cortisol and iACTH concentrations by day 2 of treatment in healthy dog, and the lower concentrations continued to day 5. One week after the last application of Fluocinonide, plasma iACTH concentrations in the corticosteroid-treated dogs has returned to the range of values for the control dogs; however, pre- and post-ACTH cortisol concentrations remains suppressed in Fluocinonide treated dogs. Two weeks after the last treatment, the pre-ACTH plasma cortisol concentrations of corticosteroid-treated dogs returns to those of the control dogs, but the post-ACTH plasma cortisol concentrations remains suppressed. |
| Animal model | |
| Formulation & Dosage | |
| References | J Drugs Dermatol. 2008 Jan;7(1):28-32; J Drugs Dermatol. 2008 Jan;7(1):28-32. |
